“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Newron has completed screening for ENIGMA-TRS 1, with 996 patients having entered screening, 411 patients already randomised and sufficient patients still in assessment to support enrolment of at least 600 participants by around mid-October. Top-line results from the primary 12-week efficacy assessment are now expected in Q127, representing an important near-term potential catalyst. The update reduces recruitment execution risk and shifts investor focus to whether evenamide can reproduce its encouraging earlier efficacy and tolerability profile in a large, randomised, placebo-controlled pivotal study.
Energy & Resources | Comment
Healthcare | Comment
Healthcare | Comment
Get access to the very latest content matched to your personal investment style.